| Aptamer-based multiplexed proteomic technology for biomarker discovery L Gold, D Ayers, J Bertino, C Bock, A Bock, E Brody, J Carter, ... Nature Precedings, 1-1, 2010 | 1604 | 2010 |
| Genomic atlas of the human plasma proteome BB Sun, JC Maranville, JE Peters, D Stacey, JR Staley, J Blackshaw, ... Nature 558 (7708), 73-79, 2018 | 1355 | 2018 |
| 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular … J Ruckman, LS Green, J Beeson, S Waugh, WL Gillette, DD Henninger, ... Journal of Biological Chemistry 273 (32), 20556-20567, 1998 | 979 | 1998 |
| Inhibitory DNA ligands to platelet-derived growth factor B-chain LS Green, D Jellinek, R Jenison, A Östman, CH Heldin, N Janjic Biochemistry 35 (45), 14413-14424, 1996 | 557 | 1996 |
| Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents JC Rohloff, AD Gelinas, TC Jarvis, UA Ochsner, DJ Schneider, L Gold, ... Molecular Therapy-Nucleic Acids 3, 2014 | 501 | 2014 |
| VEGF165 mediates glomerular endothelial repair T Ostendorf, U Kunter, F Eitner, A Loos, H Regele, D Kerjaschki, ... The Journal of clinical investigation 104 (7), 913-923, 1999 | 411 | 1999 |
| High affinity nucleic acid ligands containing modified nucleotides W Pieken, D Tasset, N Janjic, L Gold, GP Kirschenheuter US Patent 5,660,985, 1997 | 391 | 1997 |
| Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor LS Green, D Jellinek, C Bell, LA Beebe, BD Feistner, SC Gill, FM Jucker, ... Chemistry & biology 2 (10), 683-695, 1995 | 384 | 1995 |
| Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor D Jellinek, LS Green, C Bell, N Janjic Biochemistry 33 (34), 10450-10456, 1994 | 348 | 1994 |
| Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers J Floege, T Ostendorf, U Janssen, M Burg, HH Radeke, C Vargeese, ... The American journal of pathology 154 (1), 169-179, 1999 | 326 | 1999 |
| Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor D Jellinek, LS Green, C Bell, CK Lynott, N Gill, C Vargeese, ... Biochemistry 34 (36), 11363-11372, 1995 | 307 | 1995 |
| Liposome-anchored vascular endothelial growth factor aptamers MC Willis, B Collins, T Zhang, LS Green, DP Sebesta, C Bell, E Kellogg, ... Bioconjugate chemistry 9 (5), 573-582, 1998 | 303 | 1998 |
| Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets DR Davies, AD Gelinas, C Zhang, JC Rohloff, JD Carter, D O’Connell, ... Proceedings of the National Academy of Sciences 109 (49), 19971-19976, 2012 | 271 | 2012 |
| Nucleic acid ligand complexes L Gold, PG Schmidt, N Janjic US Patent 6,011,020, 2000 | 244 | 2000 |
| High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. D Jellinek, CK Lynott, DB Rifkin, N Janjić Proceedings of the National Academy of Sciences 90 (23), 11227-11231, 1993 | 222 | 1993 |
| Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis T Ostendorf, U Kunter, HJ Gröne, F Bahlmann, H Kawachi, F Shimizu, ... Journal of the American Society of Nephrology 12 (5), 909-918, 2001 | 198 | 2001 |
| Selection of DNA aptamers with two modified bases BN Gawande, JC Rohloff, JD Carter, I von Carlowitz, C Zhang, ... Proceedings of the National Academy of Sciences 114 (11), 2898-2903, 2017 | 195 | 2017 |
| Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes N Janjic, L Gold, P Schmidt, C Vargeese US Patent 6,168,778, 2001 | 187 | 2001 |
| Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes N Janjic, L Gold, P Schmidt, C Vargeese US Patent 6,051,698, 2000 | 181 | 2000 |
| Embracing proteins: structural themes in aptamer–protein complexes AD Gelinas, DR Davies, N Janjic Current opinion in structural biology 36, 122-132, 2016 | 179 | 2016 |
Thale JarvisIndependent Consultant in BiotechnologyVerified email at crestonepharma.com
